

## 1. Organize table layout:

Send Help

**Group Results By** Symptoms ▾  
**And By** None ▾  
**And By** None ▾  
**And By** None ▾  
**And By** None ▾

### Notes:

- Data contains VAERS reports processed as of **12/27/2024**.
- Must group by VAERS ID when selecting any of the Optional Measures.
- When grouping by **VAERS ID**, results are initially displayed with Events Reported, Percent, and totals not shown.

Browse Search Details

### Vaccine Products

- + LYME (LYME VACCINE (LYMERIX))
- + MM (MEASLES AND MUMPS VIRUS VACCINE, LIVE)
- + MER (MEASLES AND RUBELLA VACCINE)
- + MEA (MEASLES VACCINE)
- + MMR (MEASLES, MUMPS AND RUBELLA VIRUS VACCINE, LIVE)
- + MMRV (MEASLES, MUMPS, RUBELLA, AND VARICELLA VACCINE (PROQUAD))
- + MNQHIB (MENINGOCOCCAL GROUP C & Y + HIB)
- + MENB (MENINGOCOCCAL B VACCINE)
- + MNC (MENINGOCOCCAL CONJUGATE VACCINE)
- + MENHIB (MENINGOCOCCAL GROUPS C AND Y + HAEMOPHILUS B TETANUS TOXOID CO

### Currently selected:

\*All\* (All Vaccine Products)

## 5. Select other event characteristics:

Send Help

### Event Category

- All Events
- Death
- Life Threatening
- Permanent Disability
- Congenital Anomaly / Birth Defect \*
- Hospitalized
- Existing Hospitalization Prolonged
- Emergency Room / Office Visit \*\*
- Emergency Room \*
- Office Visit \*
- None of the above

\* VAERS 2.0 Report Form Only

\*\* VAERS-1 Report Form Only

### Recovered

- All Events
- No
- Yes
- Unknown
- Missing

### Serious

- All Events
- Yes
- No

### Vaccine Administered By

- All Entities
- Public
- Private
- Other
- Military
- Work \*
- Pharmacy \*
- Senior Living \*
- School \*
- Unknown

\* VAERS 2.0 Report Form Only

# The Vaccine Adverse Event Reporting System (VAERS) Results

Data current as of 12/27/2024

Request Form

Results

Map

Chart

Report

About

[Dataset Documentation](#)

[Other Data Access](#)

[Help for Results](#)

[Printing Tips](#)

[Help with Exports](#)

Save

Export

Reset

Quick Options

More Options

API Options

Top

[Notes](#)

[Citation](#)

[Query Criteria](#)

## Messages:

▶ VAERS data in CDC WONDER are updated every month. Hence, results for the same query can change from month to month.

▶ These results are for 1,042 total events.

▶ Rows with zero Events Reported are hidden. Use Quick Options above to show zero rows.

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 1,042) ↑↓
ABASIA	20	1.92%
ABDOMINAL DISCOMFORT	6	0.58%
ABDOMINAL DISTENSION	4	0.38%
ABDOMINAL HERNIA REPAIR	1	0.10%
ABDOMINAL PAIN	19	1.82%
ABDOMINAL PAIN UPPER	8	0.77%
ABNORMAL BEHAVIOUR	133	12.76%
ABNORMAL DREAMS	2	0.19%

MMR

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 1,042) ↑↓
<b>Total</b>	<b>7,456</b>	<b>715.55%</b>
<b>PYREXIA</b>	321	30.81%
<b>AUTISM</b>	296	28.41%
<b>SPEECH DISORDER</b>	169	16.22%
<b>APHASIA</b>	153	14.68%
<b>ABNORMAL BEHAVIOUR</b>	133	12.76%
<b>CONVULSION</b>	104	9.98%
<b>RASH</b>	100	9.60%
<b>DIARRHOEA</b>	92	8.83%
<b>AUTISM SPECTRUM DISORDER</b>	82	7.87%
<b>CRYING</b>	72	6.91%
<b>LABORATORY TEST ABNORMAL</b>	63	6.05%
<b>VOMITING</b>	62	5.95%
<b>ARTHRALGIA</b>	61	5.85%
<b>DECREASED EYE CONTACT</b>	61	5.85%
<b>IRRITABILITY</b>	60	5.76%
<b>ASTHENIA</b>	58	5.57%
<b>LETHARGY</b>	52	4.99%
<b>SCREAMING</b>	51	4.89%
<b>FATIGUE</b>	47	4.51%
<b>MENTAL RETARDATION SEVERITY UNSPECIFIED</b>	47	4.51%
<b>GASTROINTESTINAL DISORDER</b>	46	4.41%

**MMR**

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 704) ↑↓
<b>Total</b>	<b>5,299</b>	<b>752.70%</b>
<b>PYREXIA</b>	203	28.84%
<b>AUTISM</b>	181	25.71%
<b>CONVULSION</b>	106	15.06%
<b>SPEECH DISORDER</b>	91	12.93%
<b>ABNORMAL BEHAVIOUR</b>	84	11.93%
<b>APHASIA</b>	78	11.08%
<b>CRYING</b>	76	10.80%
<b>SCREAMING</b>	67	9.52%
<b>IRRITABILITY</b>	56	7.95%
<b>LETHARGY</b>	56	7.95%
<b>DIARRHOEA</b>	54	7.67%
<b>NEURODEVELOPMENTAL DISORDER</b>	53	7.53%
<b>DRUG TOXICITY</b>	45	6.39%
<b>VOMITING</b>	45	6.39%
<b>AUTISM SPECTRUM DISORDER</b>	43	6.11%
<b>NERVOUS SYSTEM DISORDER</b>	41	5.82%
<b>RASH</b>	41	5.82%
<b>DECREASED EYE CONTACT</b>	40	5.68%
<b>LABORATORY TEST ABNORMAL</b>	39	5.54%
<b>AGITATION</b>	38	5.40%
<b>ELECTROENCEPHALOGRAM ABNORMAL</b>	38	5.40%
<b>MENTAL RETARDATION SEVERITY UNSPECIFIED</b>	37	5.26%
<b>SPEECH DISORDER DEVELOPMENTAL</b>	37	5.26%
<b>DEVELOPMENTAL DELAY</b>	36	5.11%
<b>GASTROINTESTINAL DISORDER</b>	35	4.97%
<b>STARING</b>	34	4.83%

DTAP

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 381) ↑↓
<b>Total</b>	<b>2,890</b>	<b>758.53%</b>
<b>PYREXIA</b>	100	26.25%
<b>AUTISM</b>	94	24.67%
<b>CONVULSION</b>	76	19.95%
<b>SPEECH DISORDER</b>	50	13.12%
<b>ABNORMAL BEHAVIOUR</b>	46	12.07%
<b>CRYING</b>	44	11.55%
<b>SCREAMING</b>	33	8.66%
<b>DIARRHOEA</b>	31	8.14%
<b>VOMITING</b>	30	7.87%
<b>ELECTROENCEPHALOGRAM ABNORMAL</b>	27	7.09%
<b>IRRITABILITY</b>	27	7.09%
<b>LABORATORY TEST ABNORMAL</b>	27	7.09%
<b>LETHARGY</b>	27	7.09%
<b>FATIGUE</b>	24	6.30%
<b>RASH</b>	24	6.30%
<b>NEURODEVELOPMENTAL DISORDER</b>	23	6.04%
<b>APHASIA</b>	20	5.25%
<b>DEVELOPMENTAL DELAY</b>	20	5.25%
<b>HYPOTONIA</b>	20	5.25%
<b>MENTAL RETARDATION SEVERITY UNSPECIFIED</b>	20	5.25%
<b>AGITATION</b>	19	4.99%
<b>STARING</b>	19	4.99%
<b>NERVOUS SYSTEM DISORDER</b>	17	4.46%
<b>SPEECH DISORDER DEVELOPMENTAL</b>	17	4.46%
<b>DYSKINESIA</b>	16	4.20%
<b>GASTROINTESTINAL DISORDER</b>	16	4.20%

IPV (polio)

# COVID-19 vaccine

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 15,604) ↑↓
<b>Total</b>	<b>132,257</b>	<b>847.58%</b>
PAIN	2,040	13.07%
FATIGUE	2,023	12.96%
BLOOD TEST	1,843	11.81%
TINNITUS	1,837	11.77%
PAIN IN EXTREMITY	1,794	11.50%
HEADACHE	1,792	11.48%
ARTHRALGIA	1,641	10.52%
HYPOAESTHESIA	1,444	9.25%
MAGNETIC RESONANCE IMAGING	1,435	9.20%
DIZZINESS	1,359	8.71%
LABORATORY TEST	1,349	8.65%
DYSPNOEA	1,267	8.12%
ASTHENIA	1,263	8.09%
CONDITION AGGRAVATED	1,175	7.53%
COMPUTERISED TOMOGRAM	1,169	7.49%
PYREXIA	1,075	6.89%
PARAESTHESIA	1,051	6.74%
CEREBROVASCULAR ACCIDENT	989	6.34%
MUSCULAR WEAKNESS	946	6.06%
NAUSEA	911	5.84%
GAIT DISTURBANCE	888	5.69%
FEELING ABNORMAL	845	5.42%
MOBILITY DECREASED	823	5.27%
ELECTROCARDIOGRAM	810	5.19%
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	798	5.11%
IMPAIRED WORK ABILITY	792	5.08%

# Flu (injected)

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 677) ↑↓
<b>Total</b>	<b>6,430</b>	<b>949.78%</b>
PAIN	156	23.04%
PAIN IN EXTREMITY	121	17.87%
INJECTION SITE PAIN	106	15.66%
HYPOAESTHESIA	96	14.18%
MUSCULAR WEAKNESS	93	13.74%
BLOOD TEST	81	11.96%
ASTHENIA	73	10.78%
PARAESTHESIA	73	10.78%
ARTHRALGIA	71	10.49%
FATIGUE	70	10.34%
INJECTED LIMB MOBILITY DECREASED	68	10.04%
GUILLAIN-BARRE SYNDROME	62	9.16%
MAGNETIC RESONANCE IMAGING	62	9.16%
MOBILITY DECREASED	61	9.01%
HEADACHE	60	8.86%
LABORATORY TEST	59	8.71%
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES	55	8.12%
GAIT DISTURBANCE	52	7.68%
DIZZINESS	51	7.53%
PYREXIA	48	7.09%

# Flu (nasal spray)

Symptoms ↓	→ Events Reported ↑↓	← Percent (of 22) ↑↓
<b>Total</b>	<b>288</b>	<b>1,309.09%</b>
VOMITING	5	22.73%
FATIGUE	4	18.18%
HEADACHE	4	18.18%
PYREXIA	4	18.18%
ARTHRALGIA	3	13.64%
COUGH	3	13.64%
HYPERHIDROSIS	3	13.64%
INSOMNIA	3	13.64%
NARCOLEPSY	3	13.64%
NUCLEAR MAGNETIC RESONANCE IMAGING	3	13.64%
PAIN	3	13.64%
SEIZURE	3	13.64%
SOMNOLENCE	3	13.64%
ABDOMINAL PAIN	2	9.09%
AGGRESSION	2	9.09%
CATAPLEXY	2	9.09%
COMA	2	9.09%
DYSPNOEA	2	9.09%
FEELING ABNORMAL	2	9.09%
HYPERSOMNIA	2	9.09%
HYPOAESTHESIA	2	9.09%
LETHARGY	2	9.09%
MUSCLE TWITCHING	2	9.09%
MUSCULAR WEAKNESS	2	9.09%



<b>VAERS Table of Reportable Events Following Vaccination*</b>	
<b>Vaccine/Toxoid</b>	<b>Event and interval from vaccination</b>
Tetanus in any combination; DTaP, DTP, DTP-Hib, DT, Td, TT, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (3 days)</li> <li>B. Brachial neuritis (28 days)</li> <li>C. Shoulder Injury Related to Vaccine Administration (2 days)</li> <li>D. Vasovagal syncope (1 hour)</li> <li>E. Any acute complications or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Pertussis in any combination; DTaP, DTP, DTP-Hib, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (3 days)</li> <li><b>B. Encephalopathy or encephalitis (7 days)</b></li> <li>C. Shoulder Injury Related to Vaccine Administration (2 days)</li> <li>D. Vasovagal syncope (1 hour)</li> <li>E. Any acute complications or sequelae (including death) of above events (interval - not applicable)</li> <li>F. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)</li> </ul>
Measles, mumps and rubella in any combination; MMR, MMRV, MM	<ul style="list-style-type: none"> <li>A. Anaphylaxis or anaphylactic shock (3 days)</li> <li><b>B. Encephalopathy or encephalitis (15 days)</b></li> <li>C. Shoulder Injury Related to Vaccine Administration (2 days)</li> </ul>



II. Vaccines containing whole cell pertussis bacteria, extracted or partial cell pertussis bacteria, or specific	A. Anaphylaxis	<4 hours
II. Vaccines containing whole cell pertussis bacteria, extracted or partial cell pertussis bacteria, or specific pertussis antigen(s) (e.g., DTP, DTaP, P, DTP-Hib)	A. Anaphylaxis	≤4 hours.
	B. Encephalopathy or encephalitis	≤72 hours.
	C. Shoulder Injury Related to Vaccine Administration	≤48 hours.
	D. Vasovagal syncope	≤1 hour.

Page 1 of 15

Vaccine	Illness, disability, injury or condition covered	Time period for first symptom or manifestation of onset or of significant aggravation after vaccine administration
III. Vaccines containing measles, mumps, and rubella virus or any of its components (e.g., MMR, MM, MMRV)	A. Anaphylaxis	≤4 hours.
	B. Encephalopathy or encephalitis	5-15 days (not less than 5 days and not more than 15 days).

## National Vaccine Injury Compensation Program Monthly Statistics Report

Fiscal Year	Number of Compensated Awards	Petitioners' Award Amount	Attorneys' Fees/Costs Payments	Number of Payments to Attorneys (Dismissed Cases)	Attorneys' Fees/Costs Payments (Dismissed Cases)	Number of Payments to Interim Attorneys'	Interim Attorneys' Fees/Costs Payments	Total Outlays
FY 2020	733	\$186,860,677.55	\$20,165,188.43	114	\$5,774,438.88	76	\$5,090,482.24	\$217,890,787.10
FY 2021	719	\$208,258,401.31	\$24,944,964.77	140	\$6,920,048.74	52	\$4,192,522.11	\$244,315,936.93
FY 2022	927	\$195,693,889.57	\$22,992,062.07	102	\$4,868,964.74	56	\$6,329,886.09	\$229,884,802.47
FY 2023	885	\$123,810,693.81	\$35,984,811.55	126	\$6,760,733.64	61	\$7,329,281.69	\$173,885,520.69
FY 2024	1,221	\$149,653,395.87	\$38,812,164.76	125	\$8,759,507.49	51	\$5,550,091.70	\$202,775,159.82
FY 2025	241	\$29,206,706.08	\$7,366,844.28	27	\$2,486,143.10	12	\$1,311,090.18	\$40,370,783.64
<b>Total</b>	<b>11,567</b>	<b>\$4,777,785,057.60</b>	<b>\$356,451,245.26</b>	<b>6,091</b>	<b>\$121,031,299.21</b>	<b>795</b>	<b>\$67,788,957.83</b>	<b>\$5,323,056,559.90</b>

This does not include COVID vaccine injuries.

### COVID-19 claims

For claims associated with the COVID-19 vaccine or other COVID-19 related countermeasures, please file your Request for Benefits with the [Countermeasures Injury Compensation Program](#).

# Electronic Support for Public Health - Vaccine Adverse Event Reporting System (ESP:VAERS)

[Project Final Report \(PDF !\[\]\(1d3a1175dd4902218e694b9c098adb83\_img.jpg\), 96.19 KB\) Disclaimer](#)

[Project Description](#)

[Annual Summaries](#)

[Publications](#)

[Resources](#)

Adverse events from vaccines are common but underreported, with less than one percent reported to the Food and Drug Administration (FDA). Low reporting rates preclude or delay the identification of "problem" vaccines, potentially endangering the health of the public. New surveillance methods for drug and vaccine adverse effects are needed. Proactive, spontaneous, automated adverse event reporting embedded within electronic medical records (EMRs) and other information systems has the potential to speed the identification of problems with new vaccines and yield more careful quantification of the risks of older ones.

## Project Details - Completed

- **Grant Number:** R18 HS017045
- **Funding Mechanism(s):** [Ambulatory Safety and Quality Program: Enabling Quality Measurement through Health IT \(R18\)](#)

<https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-public-health-vaccine-adverse-event-reporting-system>